[go: up one dir, main page]

FR2921935B1 - Procede de criblage de composes utilisables pour le traitement de troubles respiratoires - Google Patents

Procede de criblage de composes utilisables pour le traitement de troubles respiratoires

Info

Publication number
FR2921935B1
FR2921935B1 FR0706999A FR0706999A FR2921935B1 FR 2921935 B1 FR2921935 B1 FR 2921935B1 FR 0706999 A FR0706999 A FR 0706999A FR 0706999 A FR0706999 A FR 0706999A FR 2921935 B1 FR2921935 B1 FR 2921935B1
Authority
FR
France
Prior art keywords
respiratory disorders
screening compounds
treating respiratory
functional activity
test molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0706999A
Other languages
English (en)
Other versions
FR2921935A1 (fr
Inventor
Jacques Barhanin
Christian Gestreau
Richard Warth
Dirk Heitzmann
Jorg Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Paul Cezanne Aix Marseille III
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Paul Cezanne Aix Marseille III filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR0706999A priority Critical patent/FR2921935B1/fr
Priority to PCT/FR2008/001391 priority patent/WO2009080910A2/fr
Priority to US12/681,452 priority patent/US8119362B2/en
Priority to CA2700875A priority patent/CA2700875A1/fr
Priority to EP08865189A priority patent/EP2193377A2/fr
Priority to JP2010527497A priority patent/JP2011501657A/ja
Publication of FR2921935A1 publication Critical patent/FR2921935A1/fr
Application granted granted Critical
Publication of FR2921935B1 publication Critical patent/FR2921935B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention se rapporte à l'utilisation d'un procédé de criblage pour l'identification de molécules candidates utilisables pour le traitement de troubles respiratoires chez un mammifère, ledit procédé de criblage comprenant une étape consistant à déterminer si l'activité fonctionnelle d'un polypeptide TASK-2 en présence d'une molécule test est diminuée ou supprimée par rapport à l'activité fonctionnelle dudit polypeptide TASK-2 en l'absence de ladite molécule test, la molécule test étant considérée comme étant une molécule candidate lorsqu'elle diminue ou supprime ladite activité fonctionnelle.
FR0706999A 2007-10-05 2007-10-05 Procede de criblage de composes utilisables pour le traitement de troubles respiratoires Expired - Fee Related FR2921935B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0706999A FR2921935B1 (fr) 2007-10-05 2007-10-05 Procede de criblage de composes utilisables pour le traitement de troubles respiratoires
PCT/FR2008/001391 WO2009080910A2 (fr) 2007-10-05 2008-10-03 Procédé de criblage de composés utilisables pour le traitement de troubles respiratoires
US12/681,452 US8119362B2 (en) 2007-10-05 2008-10-03 Method of screening for compounds that can be used for the treatment of respiratory conditions
CA2700875A CA2700875A1 (fr) 2007-10-05 2008-10-03 Procede de criblage de composes utilisables pour le traitement de troubles respiratoires
EP08865189A EP2193377A2 (fr) 2007-10-05 2008-10-03 Procédé de criblage de composés utilisables pour le traitement de troubles respiratoires
JP2010527497A JP2011501657A (ja) 2007-10-05 2008-10-03 呼吸器系疾患の治療に使用することができる化合物をスクリーニングする方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706999A FR2921935B1 (fr) 2007-10-05 2007-10-05 Procede de criblage de composes utilisables pour le traitement de troubles respiratoires

Publications (2)

Publication Number Publication Date
FR2921935A1 FR2921935A1 (fr) 2009-04-10
FR2921935B1 true FR2921935B1 (fr) 2011-10-28

Family

ID=39401127

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0706999A Expired - Fee Related FR2921935B1 (fr) 2007-10-05 2007-10-05 Procede de criblage de composes utilisables pour le traitement de troubles respiratoires

Country Status (6)

Country Link
US (1) US8119362B2 (fr)
EP (1) EP2193377A2 (fr)
JP (1) JP2011501657A (fr)
CA (1) CA2700875A1 (fr)
FR (1) FR2921935B1 (fr)
WO (1) WO2009080910A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202017007491U1 (de) 2016-12-02 2022-01-07 Sophion Bioscience A/S Dichtungsverstärker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040379A2 (fr) * 2003-10-23 2005-05-06 Sirna Therapeutics, Inc. Inhibition induite par interference d'arn de l'expression genique ras au moyen de petit acide nucleique interferent (sina)
WO2005054867A2 (fr) * 2003-11-25 2005-06-16 Bayer Healthcare Ag Diagnostics et therapeutique pour maladies associees au canal potassique de la sous-famille k, membre 5 (kcnk5)
US20050234000A1 (en) * 2003-12-12 2005-10-20 Mitchell Gordon S SiRNA delivery into mammalian nerve cells
DE102005044817A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
FR2921935A1 (fr) 2009-04-10
WO2009080910A2 (fr) 2009-07-02
CA2700875A1 (fr) 2009-07-02
EP2193377A2 (fr) 2010-06-09
US20110014642A1 (en) 2011-01-20
WO2009080910A8 (fr) 2010-04-29
JP2011501657A (ja) 2011-01-13
US8119362B2 (en) 2012-02-21
WO2009080910A3 (fr) 2009-09-03

Similar Documents

Publication Publication Date Title
Natarajan et al. Novel arylsulfoanilide− oxindole hybrid as an anticancer agent that inhibits translation initiation
Jadhav et al. Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease
Martínez et al. Rapid determination of ionization constants (p K a) by UV spectroscopy using 96-well microtiter plates
JP2017524130A5 (fr)
Guengerich et al. O 6-Alkylguanine-DNA alkyltransferase: Low p K a and high reactivity of cysteine 145
EP2115158A4 (fr) Traitement de donnees, et methode d'analyse de donnees d'expression de genes pour identifier les genes de reference endogenes
Cisneros et al. A fluorescence polarization assay for binding to macrophage migration inhibitory factor and crystal structures for complexes of two potent inhibitors
WO2005052592A3 (fr) Methodes et compositions pour le diagnostic, la stratification et la surveillance de la maladie d'alzheimer et d'autres troubles neurologiques dans des fluides corporels
EP2227537A4 (fr) Réacteur pour l'analyse quantitative d'acides nucléiques
BRPI0819018A2 (pt) "métodos para determinar se um paciente possui risco aumentado de desenvolver hipertensão, para determinar se um paciente possui maior probalidade de se beneficiar do tratamento com um antagonista de vegf e kits para determinar se um paciente possui risco aumentado de desenvolver hipertensão e para determinar se um paciente possui maior probabilidade de se beneficiar do tratamento com um antagonista de vegf"
WO2018049268A8 (fr) Biomarqueurs pour le diagnostic et la caractérisation de la maladie d'alzheimer
MY162697A (en) Methods, devices and kits for detecting or monitoring acute kidney injury
WO2009003905A3 (fr) Procédé pronostique pour déterminer le caractère approprié d'un traitement biopharmaceutique
ATE554389T1 (de) Apex als marker für lungenkrebs
FR2932679B1 (fr) Utilisation de l'acide ferulique ou ses derives pour ameliorer l'etat de surface d'une peau alteree.
EP2909628A4 (fr) Puce multiplexée volumétrique à diagramme à barres (puce v) pour l'analyse quantitative de biomarqueurs et/ou d'analytes hors laboratoire
Schmitz et al. Increased monocyte adhesion by endothelial expression of VCAM-1 missense variation in vitro
Ekins et al. Molecular characterization of CYP2B6 substrates
CY1110076T1 (el) Μεθοδος για τον καθορισμο της δεκτικοτητας σε αναστολεις chk1
Gehling et al. Design and synthesis of styrenylcyclopropylamine LSD1 inhibitors
FR3034523B1 (fr) Nouvelle methode pour detecter la presence de bacteries productrices de beta-lactamases.
CY1112423T1 (el) Αναλυτικη συσκευη μικροεπεξεργαστη μιας χρησης
WO2005000875A3 (fr) Compositions et procedes contenant un ligand de chemerinr
Tsotinis et al. Mapping the melatonin receptor. 7. Subtype selective ligands based on β-substituted N-acyl-5-methoxytryptamines and β-substituted N-acyl-5-methoxy-1-methyltryptamines
FR2921935B1 (fr) Procede de criblage de composes utilisables pour le traitement de troubles respiratoires

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20150630